Silver Lining In Aranesp Trial Outshines Its Two Failed Endpoints
This article was originally published in The Pink Sheet Daily
Executive Summary
Unlike previous trials, TREAT did not show a statistically significant adverse effect on all-cause mortality or cardiovascular morbidity when patients were treated to a hemoglobin target of 13 g/dL.